Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1/2 study of SNDX-5613 in relapsed or refractory acute leukemias with KMT2A rearrangement or NPM1 mutation
MOH_2023-02-19_012359Phase 2Not yet recruiting
- Sponsor
- Syndax Pharmaceuticals
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of revumenib in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and mixed phenotype acute leukemia (MPAL), sponsored by Syndax Pharmaceuticals. Primary endpoint: Safety and tolerability. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on MOH_2023-02-19_012359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-02-19_012359.